等待名单上有限度超出米兰标准的肿瘤进展不导致不可接受的生存受损
该研究分析1989年至2016年纳入肝移植等待名单的495例肝细胞癌患者,比较米兰标准内(434例)与超出米兰标准(61例)者的移植后结局。超出标准但无大血管侵犯、肝外转移或癌症相关症状者仍保留在等待名单。结果显示超出标准者复发率显著更高,但5年生存率仍高于65%的基准。
要点
- 超出米兰标准但无大血管侵犯、肝外转移或癌症症状者移植后5年生存率仍高于65%基准。
- 超出米兰标准者1、3、5、10年复发率显著高于标准内者(p<0.01)。
- 评估此类患者移植可行性时需考虑器官供应及对其他患者类别的影响。
核心结论
- 有限肿瘤进展但未达主要不良预测因素者,虽复发率预期升高,总体生存仍高于5年65%的最低基准。
研究设计与样本
- 比较米兰标准内(n=434)与超出米兰标准(n=61)两组,评估等待名单、移植前及 explant 病理的肿瘤特征。
主要发现
- 米兰标准外组最大肿瘤尺寸、BCLC分期、移植前治疗、甲胎蛋白及等待名单时间与标准内组有统计学显著差异。
- 米兰标准外组低分化结节、卫星灶及微血管侵犯数量显著更高。
- 米兰标准内/外组1、3、5、10年生存率分别为89.6%、82.5%、75%、55.5% vs. 83.6%、70.5%、65.5%、53.9%。
- 米兰标准内/外组1、3、5、10年复发率分别为1.2%、3.3%、5.5%、10.8% vs. 7.1%、14.5%、23%、23%(p<0.01)。
关键数值与推荐
- 超出等待名单标准但无大血管侵犯、肝外转移或癌症相关症状者仍保留在等待名单。
- 总体生存5年最低基准为65%。
临床怎么用
- 对等待名单上有限进展超出米兰标准但无大血管侵犯、肝外转移或癌症症状者,可考虑继续移植但需告知复发风险升高。
- 临床决策需结合器官供应情况和其他患者类别的影响综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Defining optimum management of patients progressing beyond Milan criteria on the waiting list is a controversial topic. Our aim was to determine whether the policy of allowing a limited progression beyond enlistment criteria permits acceptable post-transplant outcomes in terms of survival and recurrence. METHODS: Patients with hepatocellular carcinoma included on the waiting list for orthotopic liver transplantation (OLT) between January 1989 and December 2016 were analysed. Tumour features were assessed at inclusion on the waiting list, before OLT and at explant pathology. Patients were retained on the waiting list despite exceeding enlistment criteria if not presenting with macrovascular invasion, extrahepatic spread or cancer-related symptoms. RESULTS: A total of 495 patients constituted the target population. Comparison between the Milan-in (n = 434) and Milan-out (n = 61) groups showed statistically significant differences in: largest tumour size; BCLC stage; patients treated before OLT; alpha-fetoprotein, and time on the waiting list. Milan-out patients showed a significantly higher number of poorly differentiated nodules, satellitosis and microscopic vascular invasion. The 1-, 3-, 5- and 10-year survival rate was 89.6%, 82.5%, 75%, and 55.5%, vs. 83.6%, 70.5%, 65.5%, and 53.9% for Milan-in/Milan-out patients, respectively. Recurrence rates at 1, 3, 5 and 10 years were 1.2%, 3.3%, 5.5%, and 10.8% vs. 7.1% 14.5%, 23%, and 23% for Milan-in and Milan-out patients, respectively (p <0.01). CONCLUSION: This study shows that although limited tumour progression without reaching major adverse predictors (vascular invasion, extrahepatic spread, cancer symptoms) has an expected impact on recurrence rate, overall survival remains above the minimum proposed benchmark of 65% at 5 years. The clinically relevant increase in tumour recurrence must be considered when analysing the benefit of this approach in the face of limited organ supply. LAY SUMMARY: When considering orthotopic liver transplantation for patients with hepatocellular carcinoma, optimum results are achieved when transplanting patients within the Milan criteria. However, the most appropriate strategy for patients who progress beyond these criteria while on the waiting list is still unclear. Herein, we show that transplantation is associated with acceptable overall survival in select patients who progress beyond the Milan criteria, although recurrence rates were notably higher. Therefore, the assessment of transplantation viability in these patients must consider the availability of organs and the impact on other patient categories.
引用
- Ferrer-Fàbrega J, Sampson-Dávila J, Forner A, et al. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival. J Hepatol. 2021. PMID: 34171433. doi:10.1016/j.jhep.2021.06.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。